The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.

Details

Ressource 1Download: BIB_84CE6387A332.P001.pdf (291.64 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_84CE6387A332
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.
Journal
Neurology: Neuroimmunology & Neuroinflammation
Author(s)
Mathias A., Perriard G., Canales M., Vuilleumier F., Perrotta G., Schluep M., Du Pasquier R.
ISSN
2332-7812 (Electronic)
ISSN-L
2332-7812
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
3
Number
2
Pages
e209
Language
english
Abstract
OBJECTIVE: To assess longitudinally the antiviral immune response of T cells from patients with multiple sclerosis (MS) treated with fingolimod (FTY) vs other disease-modifying treatments (DMTs).
METHODS: We assessed cellular immune responses specific to influenza virus (FLU), JC virus (JCV), and varicella-zoster virus (VZV) using quantification of interferon-γ secretion by enzyme-linked immunospot in patients with MS on FTY (n = 31), including 2 with herpes zoster (HZ), natalizumab (n = 11), and other DMTs (n = 11). We used viral lysates for FLU and VZV and a pool of peptides for FLU, JCV (VP-1), and VZV (IE63).
RESULTS: Besides an expected drop of T cells, we found that, proportionally to the number of CD3(+) T cells, only FTY-treated patients with MS exhibited an increased VZV/IE63-specific T cell response peaking 6 months into treatment, a response that returned to baseline after 12 and 24 months. Two FTY-treated patients developed an HZ 6 months into treatment, coinciding with an absent VZV/IE63-specific T cell response. However, cellular immune responses specific to VZV lysate, JCV, and FLU (lysate and pool of peptide epitopes) were similar between all 3 categories (FTY, natalizumab, and other DMTs) of study patients.
CONCLUSIONS: FTY-treated patients with MS exhibit an increased VZV/IE63-specific cellular immune response after 6 months of treatment. FTY-treated patients who develop an HZ are not able to mount such a response, suggesting that a T cell response directed against this viral protein may be key in preventing the occurrence of HZ.
Pubmed
Open Access
Yes
Create date
27/02/2016 14:37
Last modification date
20/08/2019 14:44
Usage data